Antiepileptic-related AEs increase total costs in outpatients
- PDF / 170,321 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 91 Downloads / 186 Views
1
Antiepileptic-related AEs increase total costs in outpatients Adverse events (AEs) in patients receiving antiepileptic drugs (AEDs) appear to increase total costs of prescriptions and outpatient visits, according to findings of a US study published in Drugs - Real World Outcomes. Logistic regression analysis of US IBM Commercial and Medicare MarketScan administrative data (2014–2017) was used investigate the association between AEs and discontinuation of AEDs (≥60 days without a refill) in adults with epilepsy (inpatients and outpatients) who were new users of AEDs. The economic burden of AED discontinuation was assessed in propensity score-matched patients. The overall discontinuation rate due to AEs was 9% (0.1% based on injury codes [E-CODES], and 27% based on disease manifestation ICD* codes reported in literature or product inserts [LADE]). The rate of discontinuation was highest in patients aged 65 years or over (11%). Patients who discontinued AEDs due to AEs had more outpatient claims (19.3 vs 17.8; p
Data Loading...
